Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1(E17K)-Mutant, ER-Positive Metastatic Breast Cancer

PURPOSE: The activating mutation AKT1(E17K) occurs in ~7% of ER+ metastatic breast cancer (MBC). We report, from a multipart, first-in-human, Phase I study (NCT01226316), tolerability and activity of capivasertib, an oral AKT inhibitor, as monotherapy or combined with fulvestrant in expansion cohort...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Smyth, Lillian M., Tamura, Kenji, Oliveira, Mafalda, Ciruelos, Eva, Mayer, Ingrid A., Sablin, Marie-Paule, Biganzoli, Laura, Ambrose, Helen, Ashton, Jack, Barnicle, Alan, Cashell, Des, Corcoran, Claire, de Bruin, Elza C., Foxley, Andrew, Hauser, Joana, Lindemann, Justin P.O., Maudsley, Rhiannon, McEwen, Robert, Moschetta, Michele, Pass, Martin, Rowlands, Vicky, Schiavon, Gaia, Banerji, Udai, Scaltriti, Maurizio, Taylor, Barry S., Chandarlapaty, Sarat, Baselga, José, Hyman, David M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7415507/
https://ncbi.nlm.nih.gov/pubmed/32312891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3953
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados